🚀 go-pugleaf

Dear All

There was an article on this issue in Science (vol 286 pg 2251); it is a

complex story.  The whole case, as it stands, involves the native taq.
Three years ago Cetus were judged to have misled the patent office to
gain
the patent but the recent case was to judge if they had done so
deliberately.  Its seems they did as the Patent has now been
invalidated.
Since much of the taq sales are now based on recombinant form (covered
by a different patent) there may be little immediate impact on Roche.
However Promega plan to continue their challenge against other taq
enzymes and the PCR process itself.  The story goes on ......

David